DSY Dassault Systemes SA

Dassault Systèmes: disclosure of trading in own shares

Dassault Systèmes: disclosure of trading in own shares

Vélizy-Villacoublay, September 16, 2021

DISCLOSURE OF TRADING IN OWN SHARES

(Repurchase program decided by the General Meeting of Shareholders of May 26, 2021)

Issuer: Dassault Systèmes SE

Type of securities: ordinary shares

Period: September 8 to September 15, 2021

Detailed information (presentation by day and by market and transaction-by-transaction details) can be consulted on the website of Dassault Systèmes:

Presentation of the trading in own shares by day and by market

Name of issuerIdentification code of the issuerDate of tradingIdentification code of the financial instrumentDaily total volume (in number of shares)Daily weighted average acquisition price of the shares*Market
DASSAULT SYSTEMES96950065LBWY0APQIM868-Sep-21FR0014003TT811 11248,5000XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM868-Sep-21FR0014003TT84 02048,5000DXE
DASSAULT SYSTEMES96950065LBWY0APQIM868-Sep-21FR0014003TT82 62348,5000TQE
DASSAULT SYSTEMES96950065LBWY0APQIM869-Sep-21FR0014003TT875 49248,8076XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM869-Sep-21FR0014003TT834 15048,9063DXE
DASSAULT SYSTEMES96950065LBWY0APQIM869-Sep-21FR0014003TT86 66248,9548TQE
DASSAULT SYSTEMES96950065LBWY0APQIM8610-Sep-21FR0014003TT8195 00048,7815XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8610-Sep-21FR0014003TT860 00048,7945DXE
DASSAULT SYSTEMES96950065LBWY0APQIM8610-Sep-21FR0014003TT810 94148,9160TQE
DASSAULT SYSTEMES96950065LBWY0APQIM8613-Sep-21FR0014003TT8241 67848,5361XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8613-Sep-21FR0014003TT882 09348,5505DXE
DASSAULT SYSTEMES96950065LBWY0APQIM8613-Sep-21FR0014003TT818 45048,5804TQE
DASSAULT SYSTEMES96950065LBWY0APQIM8614-Sep-21FR0014003TT8242 08648,5480XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8614-Sep-21FR0014003TT883 62648,5535DXE
DASSAULT SYSTEMES96950065LBWY0APQIM8614-Sep-21FR0014003TT818 56948,5010TQE
DASSAULT SYSTEMES96950065LBWY0APQIM8615-Sep-21FR0014003TT8242 38549,3991XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8615-Sep-21FR0014003TT883 60549,3917DXE
DASSAULT SYSTEMES96950065LBWY0APQIM8615-Sep-21FR0014003TT818 86549,4002TQE

(*)The weighted average unit price is a rounded price

CONTACTS:

Dassault Systèmes:

Investor Relations

François-José Bordonado/Béatrix Martinez

24

 ; 

Attachment



EN
16/09/2021

Underlying

DSYDassault Systemes SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

Free Trial
DSY Dassault System...

Dassault Systemes Sa: 2 directors

Two Directors at Dassault Systemes Sa bought 30,495 shares at between 24.530EUR and 24.661EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

DSY DASSAULT SYSTEMES SA
18h / 13m 18h / 13m 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Une collaboration de plus de dix ans renforcée autour des Medidata Experiences, a pour l’objectif d’optimiser les processus et les données cliniques en améliorant la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des solutions numériques pour les essais cliniques...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration ave...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Une collaboration de plus de dix ans élargie autour des Medidata Experiences, permettant à Sanofi d’optimiser ses opérations, d’affiner la qualité de ses données et d’améliorer la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des soluti...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch